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In this issue of Immunity, the Coronin-1A gene Coro1a, which regulates cytoskeletal structure, is shown by
Haraldsson et al. (2007) to be a surprising disease-susceptibility gene that contributes to the spontaneous
systemic autoimmunity in the MRL mouse, a model of systemic lupus erythematosus.Systemic lupus erythematosus (SLE) is
a complex genetic trait, in which multi-
ple genes contribute to the development
of systemic autoimmunity. There are
pathogenic, prognostic, diagnostic, and
therapeutic arguments for identifying
lupus-susceptibility genes. However, the
challenges facing geneticists and immu-
nologists embarking on this task are con-
siderable.
Until recently, methodological and
technological limitations have hampered
gene identification in human SLE. One
strategy for circumventing these prob-
lems is to focus genetic analysis on
mouse genetic models, of which there
are several available in lupus. The MRL
mouse spontaneously develops a sys-
temic autoimmune syndrome with clinical
features reminiscent of SLE. The role of
MRL in genetic research in systemic auto-
immunity is cemented by the unveiling of
the identity of the lpr and gld phenotype
as the disease accelerating genes Fas
and FasL, respectively (Cohen and Eisen-
berg, 1991). Although the lpr mutation
arose in the CBA mouse, the effect on
autoimmunity was striking in MRL and
helped foster a major research theme:
the role of apoptosis in autoimmunity.
The work presented in this issue of
Immunity (Haraldsson et al., 2007) de-
scribes the culmination of more than a de-
cade’s work that began with mapping loci
linked with lupus traits in the genetic
crosses of MRL and B6 mice (Vidal
et al., 1998). Several loci linked with dis-
ease were mapped, including the Lmb3
locus on chromosome 7. The intervals
mapped in these linkage studies are large
and contain hundreds of genes. In an at-
tempt to localize the gene(s) that under-
pin the Lmb3 linkage, a congenic mouse
was developed. By repeated backcross-8 Immunity 28, January 2008 ª2008 Elsevieing, mice that were selected to carry
the disease-susceptibility interval Lmb3
from MRL on a B6 background were
bred. Identifying the actual polymor-
phisms that cause the disease within the
Lmb3 locus still remains a daunting
task. With the development of a congenic
mouse, the size of the congenic interval
can be gradually reduced by successive
backcrossing on large scale and select-
ing mice that continue to share the
same phenotype. However, this strategy
is time consuming and expensive, but it
has been used successfully and can
demonstrate the multiple gene involve-
ment in linkage regions in murine lupus
(Morel et al., 2001). Furthermore, no mat-
ter how intensive the breeding strategy, it
is not feasible to use breeding to identify
a single gene. TheCoro1a gene was iden-
tified by DNA sequencing rather than by
breeding additional congenic carrying
smaller regions of the MRL genome. The
transcribed portions of all the genes car-
ried within the congenic interval that
might exhibit immunological function
were sequenced in MRL and B6 mice.
At this point serendipity, a combination
of luck and insight intervened — a mis-
sense mutation was identified in the
Coro1a gene. Remarkably, this mutation
was present in the B6 mice that the inves-
tigators were studying; however, it was
absent in the mouse genome sequence
(based on B6); neither was the mutation
present in B6 mice from the Jackson Lab-
oratories or in any of the 16 other inbred
strains that were studied. Thus, this
mutation had recently arisen in the B6
mice housed at the authors’ institution
(Scripps), a mutation that generated the
Lmb3 linkage signal and was subse-
quently shown to arise in the Coro1a
gene.r Inc.The Coronin-1A gene Coro1a is, in the
mouse, one of seven Coronins. The prod-
ucts of these unlinked genes are involved
in the assembly and metabolism of cyto-
skeletal proteins. Coro1a is primarily
expressed in hematopoietic tissue. Be-
cause the gene might be considered an
‘‘unexpected’’ disease gene in SLE, the
study raises the important question—
how does the investigator move from
identification of likely causal polymor-
phisms to proving conclusively which, if
any of them, cause disease? The unique-
ness of the Coro1aLmb3 polymorphism
was a major advantage in this regard.
When attempting to pin down causal
variants, it is vital to appreciate that
the genome of inbred mouse strains
arose from a limited number of different
wild-type strains because inbred mouse
strains exhibit evidence of a block struc-
ture, reflecting regions of common ances-
try, the so-called common ancestral hap-
lotype (Wade et al., 2002). Thus, DNA
sequence analysis might reveal a string
of potential polymorphisms that could be
causal in the same haplotype block.
Defining the actual causal alleles might
require a series of complex transgenic or
gene ‘‘knockin’’ approaches. In the case
of Lmb3, the investigators were doubly
fortunate. The mutation in the B6 mice
gave them an ideal control. They were
able to show that the Coro1a gene from
the Scripps B6 substrain augmented
disease, whereas the Coro1a gene from
‘‘standard’’ B6 mice did not. This finding
rather neatly delineated themissensemu-
tation from flanking B6 genome. However,
the precise mechanism linking Coro1a
deficiency with lupus is not clear because
multiple abnormalities in T cell function in-
cluding activation, survival, and migration
were observed in Coro1aLmb3 mice. It is
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mechanisms relate to autoimmunity, al-
though transfer experiments clearly impli-
cate the T cell.
There are several noteworthy points
that arise from the identification of Coro
1aLmb3. One slightly unusual finding is that
the MRL mouse carries the resistant,
wild-type form of Coro1a, and hence the
permissive variant is carried on the dis-
ease resistant strain, namely B6. This ob-
servation has also been made in several
other models of murine lupus. What is
more unusual here is that the mutation
arose spontaneously in an isolated B6
colony. Indeed, the nature of this gene ef-
fect is likely to be the exception rather
than the rule for themolecular basis of dis-
ease genes in models of autoimmunity. It
would be anticipated that the complex
nature of the other loci, such as Sle1,
might be rather more typical (Morel
et al., 2001). It transpires that theSle1 link-
age reflects the combined influence of
at least three distinct loci. Defining the ac-
tual causal alleles in Sle1 has been ham-
pered by the tracts of shared genome
(common ancestral haplotypes), as men-
tioned above. Furthermore, the causal
alleles in complex loci such as Sle1 will
presumably exert a less penetrant effect
than the missense mutation that under-
linesCoro1aLmb. Indeed it could be argued
that Sle1, like many other loci in complex
genetic traits, was mapped because of
the close proximity of multiple disease
genes in the genome. The situation in
Lmb3 is more reminiscent of the nature
of the molecular lesions that can be
revealed by mutagenesis studies.
A gene encoding a Coronin family
member must be regarded as something
of a surprise as a disease-susceptibility
gene in lupus. No other murine or human
SLE genes have involved a gene with
a known activity that includes the struc-
tural integrity and assembly of the cyto-
skeletal structure of the cell. How relevant
is this finding to murine lupus and to hu-
man SLE? Because we do not have a de-
tailed understanding of the pathogenesis
of lupus, it is unclear whether this finding
represents a unique effect or will be an ini-
tial observation that will uncover a hitherto
unknown aspect of pathology in autoim-
munity. Certainly no disease genes identi-
fied thus far bear a known functional
relationship with the Coronins. However,
only a handful of disease-susceptibilityFigure 1. Genes Associated with Murine Lupus and Human SLE
The figure conveys the outcome of genetic risk in SLE. Only genes showing replication and/or corrobora-
tion are shown. The only protective haplotype shown is themouseMHC,which has been subject to several
studies, and there is evidence for suppressive gene effects and a hierarchy of risk for murine lupus. The
actual causal alleles that contribute within the H2 region remain to be established. The susceptibility clus-
ter away from the fulcrum shows single-gene mutations (or duplication in the case of Tlr7) that accelerate
the disease phenotype. TheCoro1a gene is placed to the right because the mutation is protective. For hu-
man, the genes closest to the fulcrum represent genes whose risk alleles or haplotypes are relatively com-
mon variants in the population. Genes with a higher penetrance are shown at greater distance from the
fulcrum, although these are due to alleles with a low frequency (as indicated by the smaller size of the
gene box). Although only C1Q has been listed, complete genetic deficiencies of other classical comple-
ment-pathway proteins also predispose to SLE; the role of partial deficiency states has not been fully es-
tablished. The genetic contribution from the immunoglobulin Fcg receptor locus in SLE is complex. There
are weak effects from FCGR2A and FCGR3A and a stronger effect due to copy-number variation that
involves FCGR3B. In the latter case, the superscript 0 or 1 refers to less than the expected diploid copy
number, and the superscript 3+ refers to a greater than expected number.genes have thus far been identified in lu-
pus (Figure 1). The nature of the molecular
lesion in Coro1a makes this finding more
akin to lpr, gld, and the recently defined
Tlr7 duplication that underlies the Yaamu-
tation (Deane et al., 2007). Interestingly,
the phenotype associated with Coronin-
1A deficiency is likely to vary according
to the genetic context. Mice with a gene-
targeted deletion of Coro1a (Fo¨ger et al.,
2006) do not exhibit the same degree of
immunological abnormities as observed
by Haraldsson et al. (2007). The abnor-
malities in T cell function in this latter
study were predominantly detected in
MRL.B6-Lmb3 Faslpr mice, specifically
MRL mice that also carried the lpr muta-
tion and theCoro1aLmb3mutation. It is im-
portant to appreciate that these two mu-
tations differ in that the lpr mutation
might be considered analogous to a low-
frequency variant, in human SLE, that en-
hances risk. The Coro1a gene effect isImmuonly observed because of a protective
mutation in the nondiseased B6 breeding
partner. This mutation might be consid-
ered as a rare protective variant. Such
mutations will not be readily detectable
in humans and will only be identified fortu-
itously in the mouse. However, strategies
involving ENU mutagenesis can be made
to generate protective mutations in
disease-prone mice, which would be par-
ticularly appealing as a source of thera-
peutic targets.
In humans, rare more penetrant muta-
tions have been identified, such as
complement C1q-deficiency and more
recently mutations in the exonuclease
TREX1 (Lee-Kirsch et al., 2007) (Figure 1).
Rare mutations in human disease are dif-
ficult to identify because of the large
numbers of DNA sequencing required,
but the advent of new, cheaper sequenc-
ing technologies should facilitate the
use of large-scale sequencing projects.nity 28, January 2008 ª2008 Elsevier Inc. 9
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iation in the heterogeneity of such rare
mutations in human SLE. Although rare
protective genetic variants in SLE proba-
bly exist in human SLE, it will not be pos-
sible to prove their existence in the ab-
sence of a complete predictive model of
disease.
Progress in identifying disease-suscep-
tibility genes in SLE is entering an expo-
nential phase of productivity. The advent
of genome-wide association studies in
humans has the potential to reveal the
majority of the main disease-susceptibil-
ity-gene effects that are related to rela-
tively common variants in the human
genome. These approaches have been
highly successful in a number of autoim-
mune diseases. Thus, to some extent,
the primary vehicle for disease-gene dis-
covery has moved away from animal
models and back to man. The results of
these genome-wide analyses, and thoseHIV-1 Hides an Ac
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(gp41) envelopepeptide in lipids. Th
The development of a safe and effective
HIV-1 vaccine is one of the highest scien-
tific priorities. One of the many road-
blocks to AIDS vaccine development is
the inability of the HIV-1 cell-surface en-
velope-protein complex (HIV-1 Env) to in-
duce broadly neutralizing antibodies. The
HIV-1 envelope-protein complex consists
of two covalently linked glycoprotein (gp)
components, the outer gp120 piece and
the gp41 component that connects with
a transmembrane domain [reviewed in
(Eckert and Kim, 2001; Haynes and Mon-
tefiori, 2006)]. HIV-1 Env glycoproteins
have conserved functional regions to
which broadly neutralizing antibodies
could, in theory, bemade. However, these
10 Immunity 28, January 2008 ª2008 Elsevhigher-density scans that will undoubt-
edly follow, will allow the assembly of
the basic genetic components of SLE
and other autoimmune diseases, if suffi-
cient sample sizes can be gathered. The
question of the relevance of murine lupus
to human SLE might then be more readily
addressed. However, identifying large
numbers of rare predisposing variants in
human SLE awaits further reduction in
the costs of DNA sequencing, and identi-
fying rare protective variants, analogous
to Coro1aLmb3 mutation is not attainable
at present.
The field of SLE genetics is poised to
yield up its main secrets. The process of
evaluating all the pathogenic implications
is an exciting and immediate prospect.
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